Shanghai Xinfan Bio: Large inventory: the world's top 10 biopharmaceutical companies with good "genes"

Although there are at least dozens of biopharmaceutical companies in the world that contain "gene" in whole or in part, there is no intention to list them in this article. I have selected 10 companies (in alphabetical order by company). The list company is the most famous biopharmaceutical company with all or part of its name containing “gene”.

For a newborn child, having a good genetics and having a good name is important, as is the case for a company. At present, there are only tens of thousands of biopharmaceutical companies in the world, and the company's name is also diverse, but one word in the company's name seems to be the most popular, it is "gene" (gene).

This article is the most famous biopharmaceutical company that has all or part of its name containing "gene" (but also includes several small companies that I am familiar with and interested in). Biopharmaceutical companies that include "gene" in whole or in part of the global name have at least dozens of them in the United States alone, but this article does not intend to list them. The following table shows the 10 companies that have been screened by themselves (in alphabetical order by company).

company name

Chinese translation

Year of establishment

headquarter

Company website

Am gen

Amgen

1980

California

Amgen.com

Bio gen

Idec (renamed Biogen)

Baijian Eddie

1978

Massachusetts, USA

Biogenidec.com

Can gene

?

1984

Canada

Cangene.com

Cel gene

Xaar Gene / New Base

1986

New Jersey, USA

Celgene.com

Gene ntech

Genek

1976

California

Gene.com

Gen mab

?

1999

Denmark

Genmab.com

Gen zyme

Genzan

1981

Massachusetts, USA

Genzyme.com

Immuno gen

?

1981

Massachusetts, USA

Immunogen.com

Medi gene

?

1994

Germany

Medigene.com

Re gene ron

Regeneration element

1988

New York State

Regeneron.com

As can be seen from the table, these 10 companies have the following characteristics:

1. In addition to the three smaller companies in Denmark, Germany and Canada, the remaining seven companies are located in the United States and are concentrated on the east and west coasts of the United States. But these seven companies are not all American companies in the true sense, because Genentech and Genezyme have been acquired by Swiss Roche and Sanofi, respectively, as European companies. At present, Amgen is the largest independent biotechnology company in the world.

2. In addition to the above two European companies established in the 1990s, most of them were established in the late 1970s and early 1980s. Among them, Genentech was first established (1976), and it is also the world's first biotechnology company and the most famous. One of the biological companies.

3. The main businesses of 10 biopharmaceutical companies are not all biotech drugs.

The 10 companies have two exceptions: Biogen Idec and Celgene, both of which are already marketed as small molecule chemicals, although their company names look "bio". In addition, Biogen Idec combined with Biogen and Idec is very similar to biogenetic. It sounds more like a pure biotech company. Biogen Idec has significant advantages in neurological and psychotropic drugs. It has a variety of original drugs for the treatment of multiple sclerosis (MS). In August 2014, another new drug for the treatment of MS was approved by the US FDA. (Bio-Exploration Editor added: Biogen Idec, just announced last month, announced the launch of the new company name Biogen, which is now closer to the "gene".)

4, 10 companies have unique skills, each with their own strengths.

The old saying "a fresh trick, eat all over the sky" seems to apply to the young biopharmaceutical field. For example, in addition to the above-mentioned Bai Jian's expertise in neurological and psychiatric drugs, Immunogen has a small size, but it also has a hand: IP-based antibody-conjugated drug (ADC) technology platform, Roche (Genentech) FDA-approved ADC new drug Kadcyla in 2013 is based on the company's technology, ADC technology is now the absolute high in the global biopharmaceutical, but also research and development hotspots There are very few companies that have mastered the technology and have patents (another famous company in the field is Seattle Genetics).

A brief introduction to ADC technology and Kadcyla's new drug can be found in another blog post on the BioExploration website: New drugs approved by the US FDA in the first half of 2013. China seems to have made breakthroughs in this field recently. According to media reports, Hengrui Medicine established China's first ADC drug technology platform, achieving China's zero breakthrough in this field. However, I personally think that whether Hengrui truly masters the technology, is Hengrui a fully self-developed technology platform (there is no patent infringement problem?). It still needs time to observe.

5, Regeneron (Regeneron) drug company can be described as a dark horse in the field of biopharmaceuticals.

In recent years, regenerative sales and stock prices have risen tremendously. The company’s stock price now (August 27, 2014) has exceeded $350 per share, which is what I know as a single company in the biopharmaceutical sector. The highest share price, the author reprinted this article when the stock price reached 461.39 US dollars. The company has such good performance, the income of the company's CEO is naturally low. In fact, the CEO of Renaissance is the highest income in the global biopharmaceutical (including chemical) field, and the annual income in 2012 exceeded 30 million US dollars.

6. In addition to Genentech and Genzyme, which are not independent biotech companies, the Canadian company Cangene was also acquired by Emergent Biosolutions in the US for $222 million at the beginning of this year.

Unlike the fate of big biotech companies like Genentech and Genzan, Cangene's name will no longer exist after the merger, and it will become history. In addition, I believe that in addition to Amgen's large scale and difficult to be merged, several independent biotech companies in the table (especially the one-of-a-kind Immunogen) are likely to be acquired by other big companies in the next few years. So now small innovative biotech companies have encountered unprecedented opportunities in history.

7. In the biological field, the most familiar biological term should be a few words, such as DNA, RNA, gene, protein, enzyme, cell, etc. Making a two-two combination as a company name seems like a good choice.

In fact, Celgene (cell+gene) and Genzyme (gene+enzyme) in the table are just like this. Another biopharmaceutical star, Epizyme, is also a hero. The company specializes in the development of epigenetic-related anticancer drugs, and Epizyme's name is a combination of epigenetics and enzymes.

8. Some of the 10 large companies have entered China.

As the world's largest independent biotechnology company, Amgen entered China in 2012 and established a branch office in Shanghai. It decided to develop biosimilars together with Chinese cooperative companies. In 2013, the newly established university of the Chinese Academy of Sciences--Shanghai University of Science and Technology (note: not the one that had already merged with Shanghai University) cooperated to establish the Amgen China R&D Center;

Although Baijian Aidi has not yet opened a branch in China, it has recently signed an exclusive contract with its partner, the famous European pharmaceutical company UCB. The two companies have jointly developed and sold new drugs in mainland China, and at the same time exclusively authorized UCB in Asia. South Korea, China's Hong Kong and Taiwan regions, Thailand, Singapore and Malaysia sell Baijian Eddie's drugs;

Xaar Gene (Xinji Company) also has offices in Beijing, Shanghai, Hong Kong and Taiwan.

Genzyme and Shire are the two most famous companies in the world specializing in orphan drugs for the treatment of rare diseases. In October 2012, the company's parent company, Sanofi, signed a memorandum of cooperation with the China National Institute of Pharmaceutical Industry to jointly conduct a joint study on the diagnosis and treatment of diseases in the rare disease field in China.

Gianzan currently has many orphan drugs for the treatment of a variety of rare diseases, the most famous of which is the orphan drug for the treatment of Gaucher disease - Cerezyme, who started to cooperate with the Chinese government in 1999 to present the drug to Chinese patients. The market value of Chinese patients donating the drug has exceeded 100 million euros. The drug was finally officially listed in China at the end of 2008. The drug is called imiglucerase in Chinese. The trade name: think and praise, like other orphan drugs, the drug is expensive.

Finally, what puzzles the author is that the famous Genentech does not seem to have entered China at present (at least not on the Internet), although its parent company, Roche, opened a branch in China more than 20 years ago (1994).

Edit Comment:

Have you heard of or seen other companies with "gene" in whole or in part? Are there any special stories behind their growth? Welcome to leave a message or come and share with us.

Elisa

Kit

, elisakit,

Shanghai

Elisa

Experimental survey

, SOD

Kit

, IgG

Kit

, IgM

Kit

, WB

Experimental generation

,

Immunohistochemistry experiment

,

Free test

,GIBCO,AMRESCO-

Shanghai Xinfan Biological